American Portfolios Advisors Incyte Corp Transaction History

American Portfolios Advisors

$2.36 Trillion
Q3 2022

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Mar 21, 2023	BUY	$66.02 - $79.71 $77,705 - $93,818	1,177 New	1,177 $93.5 Million
Q4 2021 Mar 21, 2023	BUY	$63.34 - $74.11 $82,151 - $96,120	1,297 New	1,297 $95.2 Million
Q3 2021 Mar 22, 2023	BUY	$68.67 - $84.02 $16,480 - $20,164	240 New	240 $16.5 Million
Q2 2021 Mar 22, 2023	BUY	$79.87 - $87.53 $9,584 - $10,503	120 New	120 $10.1 Million
Q1 2021 Mar 22, 2023	BUY	$76.02 - $100.5 $13,683 - $18,090	180 New	180 $14.6 Million
Q4 2020 Mar 22, 2023	BUY	$80.74 - $97.7 $3,956 - $4,787	49 New	49 $4.26 Million
Q3 2020 Mar 22, 2023	BUY	$85.07 - $109.69 $3,232 - $4,168	38 New	38 $3.41 Million
Q2 2020 Mar 24, 2023	SELL	$74.18 - $108.93 $8,901 - $13,071	-120 Reduced 69.77%	52 $5.41 Million
Q1 2020 Mar 24, 2023	BUY	$63.18 - $85.97 $10,866 - $14,786	172 New	172 $12.6 Million
Q4 2019 Mar 24, 2023	BUY	$73.04 - $95.72 $12,562 - $16,463	172 New	172 $15 Million
Q3 2019 Mar 24, 2023	BUY	$72.82 - $86.52 $2,184 - $2,595	30 Added 21.13%	172 $12.8 Million
Q2 2019 Mar 24, 2023	BUY	$73.52 - $88.7 $10,439 - $12,595	142 New	142 $12.1 Million
Q1 2019 Mar 24, 2023	BUY	$63.56 - $88.17 $38,771 - $53,783	610 Added 327.96%	796 $68.5 Million
Q4 2018 Mar 24, 2023	SELL	$58.5 - $69.94 $58,968 - $70,499	-1,008 Reduced 84.42%	186 $11.8 Million
Q3 2018 Mar 24, 2023	BUY	$61.75 - $74.23 $73,729 - $88,630	1,194 New	1,194 $82.5 Million
Q2 2018 Mar 24, 2023	BUY	$60.85 - $83.98 $10,648 - $14,696	175 Added 18.64%	1,114 $74.6 Million
Q1 2018 Mar 24, 2023	BUY	$83.06 - $100.98 $77,993 - $94,820	939 New	939 $78.2 Million
Q4 2017 Mar 24, 2023	BUY	$93.56 - $116.6 $30,687 - $38,244	328	328 $31.1 Million

Others Institutions Holding INCY

# of Institutions

657

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Account